Jaguar Health, Inc. (JAGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. on December 30, 2022, covering events occurring on December 27, 2022. The Company is incorporated in Delaware and trades on the NASDAQ Capital Market under the symbol JAGX.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a specific corporate action regarding equity compensation.
Material Changes and Corporate Actions
On December 27, 2022, the Company entered into Stock Option Cancellation Agreements with certain executive officers. Key details include:
- Cancelled Options: An aggregate of 315,131 shares of Common Stock underlying previously granted options were surrendered and cancelled.
- Exercise Price: The cancelled options had an exercise price of $5.97 per share.
- Consideration: The Company agreed to pay $300 to each participating Executive Officer in consideration for the cancellation.
- Participants: The agreements involved Lisa A. Conte (CEO), Carol Lizak (CFO), Dr. Steven R. King, Jonathan Wolin, and other executive officers.
- Breakdown of Shares:
- Lisa Conte: 142,500 shares
- Dr. Steven King: 42,223 shares
- Carol Lizak: 14,294 shares
- Jonathan Wolin: 21,112 shares
- Other Executive Officers: 95,002 shares
- Impact: The options were scheduled to vest ratably over 36 months, with full vesting expected on April 5, 2024. The cancellation is expected to benefit stockholders' equity in each of the next five quarters by reducing future stock-based compensation expense.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or new risk factors. The primary contingency noted is the execution of the Cancellation Agreements, the full text of which is filed as Exhibit 10.1.
Key Facts for Investor Verification
- Verify the reduction in future stock-based compensation expense in upcoming quarterly reports.
- Confirm the impact on the Company's diluted share count and stockholders' equity.
- Review Exhibit 10.1 for the full legal terms of the Cancellation Agreements.
- Note that the filing does not disclose any changes in the Company's core business operations or financial health beyond the option cancellation.